Sonoma Biotherapeutics
PrivateLast Round
Strategic
Mar 28, 2023
Total Funding Raised
$365M
Company Overview
Sonoma Biotherapeutics is a biotechnology company that develops engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Sonoma Biotherapeutics Comparables
Compare Sonoma Biotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| GentiBio | 86% | |
| Quell Therapeutics | 84% | |
| Tr1X | 84% | |
Sonoma Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Mar 28, 2023 | ||||
| Series B | Aug 4, 2021 | ||||
| Series A Extension | Sep 30, 2020 | ||||
| Series A | Feb 6, 2020 |
Sonoma Biotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Janus Henderson Group | Series B |
| Frazier Healthcare Partners | Series B |
| Vertex Ventures HC | Series B |
| GV | Series B |
| Mirae Asset | Series B |
| Octagon Capital Advisors | Series B, Series A Extension |
| Ally Bridge Group | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 4, 2025
Expediting G-Rex manufacturing process for autoimmune disorder therapies.
- Aug 26, 2025
Lisa Taylor Ash appointed as new Chief Legal Officer.
Sonoma Biotherapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Sonoma Biotherapeutics's valuation, stock price, and market status.